Posted by Michael Wonder on 12 Nov 2024
Genascence granted FDA fast track designation for GNSC-001 in patients with osteoarthritis of the knee
12 November 2024 - GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint; IL-1 is a key mediator involved in pathogenesis of osteoarthritis.
Genascence today announced the US FDA has granted fast track designation for GNSC-001, a potential first in class gene therapy for the treatment of patients with osteoarthritis of the knee.
